Opella

Opella Healthcare Group S.A.S., doing business as Opella, and formerly Sanofi Consumer Healthcare (CHC), is a French multinational pharmaceutical company specializing in consumer healthcare products. Opella's activities include dietary supplements and over-the-counter medicines such as Mucosolvan (ambroxol), Allegra (fexofenadine), and the French brand Doliprane (paracetamol). Until 2024, Opella was wholly owned by French pharmaceutical company Sanofi, at which point it sold 50% of the subsidiary to US private equity fund CD&R. Sanofi retains 48.2% of Opella, while France's public investment bank, Bpifrance, has acquired 1.8%. In the US, Sanofi Consumer Healthcare, then Opella, owns 100% of Chattem, Inc., doing business as Sanofi Consumer Health North America, then Opella North America.